MALVERN, Pa., June 14, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM) a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that all Resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's website at www.realmtx.com.
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signaling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development program utilizes the Company's proprietary immunomodulatory technology for the treatment of Atopic Dermatitis, and the Company is exploring its efficacy in other dermatology indications which include Acne Vulgaris, and Psoriasis, as well as other therapeutic areas. For more information on Realm Therapeutics please visit www.realmtx.com.
View original content:http://www.prnewswire.com/news-releases/realm-therapeutics-announces-results-of-2018-annual-general-meeting-300666342.html
SOURCE Realm Therapeutics
Realm Therapeutics plc: Alex Martin, Chief Executive Officer; Marella Thorell, Chief Financial Officer and Chief Operating Officer, Outside US: +44 (0) 20 3727 1000, US: +1 212 600 1902; Argot Partners: Stephanie Marks / Susan Kim, +1 212 600 1902; FTI Consulting: Simon Conway / Mo Noonan, +44 (0) 20 3727 1000; N+1 Singer (Nominated Adviser and Broker): Aubrey Powell / Jen Boorer, +44 (0) 20 7496 3000